 Expanded clinical evaluation lovastatin EXCEL study results IV Additional tolerability lovastatin randomized double-blind multicenter diet-and-placebo-controlled study dose-response relationship lovastatin therapy lipid-modifying efficacy drug-related adverse events Exclusion criteria study patients representative majority patients moderate hypercholesterolemia medical practice weeks American Heart Association Step Diet total patients weeks treatment diet placebo lovastatin dosages mg day mg day adverse events particular attention evaluation liver muscle Liver transaminase elevations possible hepatotoxicity successive elevations aspartate transaminase alanine aminotransferase times upper limit normal equal numbers placebo mg/day patients frequencies lovastatin mg/day mg/day patient groups patient symptomatic hepatic dysfunction Creatinine kinase CK elevations upper limit normal placebo- lovastatin-treated patients muscle symptoms similar frequency groups combination muscle symptoms marked CK elevations times upper limit normal patients mg/day group mg/day dose group patient rhabdomyolysis incidence clinical laboratory adverse events discontinuation placebo group mg/day mg/day lovastatin treatment groups new types adverse experiences treatment Lovastatin adjunct reduction elevated LDL cholesterol